Maia Biotechnology Inc., a clinical-stage biopharmaceutical company, has announced its participation in the upcoming BIO International Convention 2025, scheduled for June 16-19 in Boston, Massachusetts. During the event, Chairman and CEO Vlad Vitoc, MD, MBA, will present the latest findings from the company's THIO-101 Phase 2 clinical trial on June 18 at 11:30 AM EDT. The trial evaluates ateganosine (THIO), a small molecule telomere-targeting anticancer agent, sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC). The results of the trial, which aim to be the first completed clinical study of a telomere-targeting agent in cancer treatment, have not yet been presented and are expected to be disclosed during this session. The company has also announced the expansion of the trial to further assess the efficacy of the treatment in third-line NSCLC patients.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.